ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc (VRPX)

1.28
-0.17
(-11.72%)
Closed July 19 3:00PM
1.28
0.00
(0.00%)
After Hours: 6:58PM

Your Hub for Real-Time streaming quotes, Ideas and Live Discussions

Key stats and details

Current Price
1.28
Bid
1.28
Ask
1.35
Volume
583,893
1.26 Day's Range 1.50
0.4603 52 Week Range 10.00
Market Cap
Previous Close
1.45
Open
1.44
Last Trade Time
Financial Volume
US$ 786,549
VWAP
1.3471
Average Volume (3m)
5,548,225
Shares Outstanding
1,171,233
Dividend Yield
-
PE Ratio
-0.10
Earnings Per Share (EPS)
-12.97
Revenue
-
Net Profit
-15.19M

About Virpax Pharmaceuticals Inc

Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray. Virpax Pharmaceuticals Inc is a preclinical stage biopharmaceutical company. The company is focused on developing pharmaceutical product candidates for pain management. Its product portfolio includes Topical metered-dose spray; Liposomal in Hydrogel encapsulation; and Enkephalin Intranasal spray.

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Headquarters
Wilmington, Delaware, USA
Founded
1970
Virpax Pharmaceuticals Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker VRPX. The last closing price for Virpax Pharmaceuticals was US$1.45. Over the last year, Virpax Pharmaceuticals shares have traded in a share price range of US$ 0.4603 to US$ 10.00.

Virpax Pharmaceuticals currently has 1,171,233 shares outstanding. The market capitalization of Virpax Pharmaceuticals is US$1.70 million. Virpax Pharmaceuticals has a price to earnings ratio (PE ratio) of -0.10.

VRPX Latest News

Virpax Announces Positive Results of Swine Model Pilot Study for Probudur™

Virpax® Pharmaceuticals, Inc. (“Virpax” or the “Company”) (NASDAQ: VRPX), a company specializing in developing non-addictive products for pain management, post-traumatic stress disorder, central...

Period †ChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.45-26.01156069361.732.091.0544381141.51368653CS
40.72128.5714285710.563.390.4603161604291.36384554CS
12-1.78-58.16993464053.063.390.460355482251.3481596CS
26-1.72-57.333333333335.480.460325619211.37787859CS
52-8.52-86.93877551029.8100.460313465191.54085458CS
156-48.72-97.4450359.7990.460396942167.02131949CS
260-78.72-98.480359.7990.4603100502465.68495759CS

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TNZTenaz Energy Corp
$ 5.73
(56.13%)
1.11M
VRTSGamelancer Media Corp
$ 0.02
(33.33%)
108.1k
NCFNorthcliff Resources Ltd
$ 0.025
(25.00%)
1.75k
IVQ.UInvesque Inc
US$ 0.15
(15.38%)
5k
AMMAlmaden Minerals Ltd New
$ 0.08
(14.29%)
70k
HWOHigh Arctic Energy Services Inc
$ 0.84
(-45.45%)
70.17k
AVCNAvicanna Inc
$ 0.365
(-17.05%)
166.2k
BCTBriaCell Therapeutics Corp
$ 1.05
(-16.00%)
145.63k
PNC.APostmedia Network Canada Corp
$ 1.33
(-13.64%)
801
VGCXVictoria Gold Corp
$ 0.67
(-12.99%)
1.13M
CNQCanadian Natural Resources Ltd
$ 48.92
(0.18%)
14.63M
RYRoyal Bank of Canada
$ 153.71
(0.25%)
8.73M
ENBEnbridge Inc
$ 49.74
(0.32%)
8.35M
ABXBarrick Gold Corporation
$ 25.41
(-1.70%)
7.06M
SUSuncor Energy Inc
$ 53.25
(0.15%)
6.74M

VRPX Discussion

View Posts
Timing101 Timing101 5 hours ago
Any type of Catalyst(s) comes out , which is very likely , this will take off.
👍️0
glenn1919 glenn1919 3 days ago
VRPX........................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783
👍️0
Dantheoneman Dantheoneman 1 week ago
Weeeeeeee
👍️0
TrendTrade2016 TrendTrade2016 1 week ago
vprx...monster pre to open
👍️0
Invest-in-America Invest-in-America 1 week ago
VRPX: Yep!!! And now PIGS don't have suffer PAIN anymore!!!! (But, what about we HUMANS???!!!)
👍️0
Awl416 Awl416 1 week ago
Virpax Announces Positive Results of Swine Model Pilot Study for Probudur
👍️0
Invest-in-America Invest-in-America 2 weeks ago
VRPX: Still kickin' myself for stupidly-misinterpreting their PR as classic FLUFF NEWS. (Which indeed it still was, despite what anybody says!!! WOW!!! they got $2.5-Mil. FINANCING, so they don't fold-up-shop!!! GOD bless them!!!!)
😭 1
tw0122 tw0122 2 weeks ago
today announced that it has closed a $2.5 million secured loan financing from an institutional investor which enabled the final payment of its litigation settlement. As part of this financing, the Company’s Board of Directors has been reorganized, and has been reduced to seven members from eight. Four new board members have been selected by the institutional investor and appointed to the Board, and five Board members have resigned.

“This loan by the institutional investor, combined with an agreement to negotiate additional funding, will allow us to continue fulfilling our mission to develop non-addictive pain drugs as well as other CNS product candidates with high unmet medical need,” stated Gerald Bruce, CEO of Virpax Pharmaceuticals. “We believe we have a valuable portfolio of assets which was confirmed to us by the high level of interest we received at the recent BIO meeting in San Diego. Our new funding relationship gives us the confidence and flexibility to fund our programs moving forward.”

Additionally, Virpax announced the changes to its Board of Directors with the appointments of Ms. Judy Su, Mr. Gary Herman, Mr. Jatinder Dhaliwal and Ms. Katharyn Field. Resignations from Virpax’s Board were tendered effective upon consummation of the financing by Dr. Jeffrey Gudin, Dr. Thanigavelan Jambulingam, Mr. Michael Dubin, Mr. Jerrold Sendrow and Dr. Barbara Ruskin.

“We are excited to welcome our new Board members whom we anticipate will bring expertise and fresh vision to assist us as we move into our next stage of development. We expect to begin first-in-human trials in 2025,” continued Mr. Bruce.

Ms. Judy Su was lead pharmacist at a national drug store for six years and has knowledge and experience of large-scale retail distribution of scheduled drugs and medications. Currently, Ms. Su works as a pharmacist in the public sector. She has years of experience serving as an independent director for multiple publicly traded companies listed in Canada (CSE,TSX). Judy graduated in 2012 at the University of British Columbia with a bachelor's degree in pharmacy.

Mr. Gary Herman is a seasoned investor. From 2006 until 2021, he co-managed Strategic Turnaround Equity Partners, LP (Cayman), and from 2005 until 2020 he was affiliated with Arcadia Securities LLC. Gary’s expertise extended to his role as a managing member of Abacoa Capital Management, LLC from January 2011 until August 2013, where his focus centered on the Global-Macro investment strategy. His background also includes tenure as an investment banker at Burnham Securities, Inc., a managing partner of Kingshill Group, Inc., and as a director for various public company boards. Mr. Herman received a B.S. in Political Science from the University at Albany, with minors in Business and Music.

Mr. Jatinder (Jay) Dhaliwal is a registered pharmacist and has served as CEO and director of multiple publicly traded companies listed on Canadian (CSE, TSX) and American (Nasdaq) exchanges. Mr. Dhaliwal is currently a director of a Nasdaq listed leading seed to patient cannabis producer in Europe as well as serving as an independent director of a Nasdaq listed premier marketing agency specialized in the liquor industry. Previously, he worked in an upper management role in a large national pharmacy and has extensive knowledge in agricultural, medical and pharmaceutical operations. Mr. Dhaliwal holds a Bachelor of Pharmacy from the University of British Columbia and a Bachelor of Science in biology from the University of Victoria.

Ms. Katharyn (Katie) Field’s background includes positions spanning both the private and public sectors and brings a wealth of experience and expertise in strategy consulting and executive leadership. Ms. Field is currently the CEO and Chairman of Halo Collective Inc., an Executive Director at Akanda Corporation, and the Chairperson of Aerwins Technology. She has held prominent positions at renowned organizations including in the White House in the office of the public liaison, the Brookings Institution as a manager of operations, and Bain & Company as a consultant. In 2014, Ms. Field entered the cannabis industry working with one of the original vertically integrated licensed medical marijuana treatment centers in Florida. Subsequently, she operated a strategy consulting practice focused on cannabis and served as Executive Vice President of Corporate Development at MariMed from 2018 to 2019. Ms. Field holds an MBA from Columbia Business School and a BA with honors from Stanford University.

“We are grateful to the outgoing Board members and thank them for their support and contributions,” concluded Mr. Bruce.

About Virpax Pharmaceuticals

Virpax is developing branded, non-addictive pain management products candidates using its proprietary technologies to optimize and target drug delivery. Virpax is initially seeking FDA approval for two prescription drug candidates that employ two different patented drug delivery platforms. Probudur™ is a single injection liposomal bupivacaine formulation being developed to manage post-operative pain and Envelta™ is an intranasal molecular envelope enkephalin formulation being developed to manage severe pain, including post cancer pain. Virpax is also using its intranasal Molecular Envelope Technology (MET) to develop one other prescription product candidate, NobrXiol™, which is being developed for the nasal delivery of a pharmaceutical-grade cannabidiol (CBD) for the management of rare pediatric epilepsy. Virpax has competitive cooperative research and development agreements (CRADAs) for two of its prescription drug candidates, one with the National Institutes of Health (NIH) and one with the Department of Defense (DOD). Virpax is also seeking approval of two nonprescription product candidates: AnQlar, which is being developed to inhibit viral replication caused by influenza or SARS-CoV-2, and Epoladerm™, which is a topical diclofenac spray film formulation being developed to manage pain associated with osteoarthritis. For more information, please visit virpaxpharma.com and follow us on Twitter, LinkedIn and YouTube.
👍️0
tw0122 tw0122 2 weeks ago
Not a bad day
👍️0
TheFinalCD TheFinalCD 2 weeks ago
tint float with news
👍️0
glenn1919 glenn1919 2 weeks ago
VRPX......................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783
👍️0
Renee Renee 5 months ago
VRPX: effective March 1,2024 a one for 10 reverse split:

https://hedgefollow.com/upcoming-stock-splits.php
👍️0
glenn1919 glenn1919 7 months ago
VRPX...........................................https://stockcharts.com/h-sc/ui?s=VRPX&p=W&b=5&g=0&id=p86431144783
👍️0
TheFinalCD TheFinalCD 7 months ago
whats the latest here? https://finviz.com/quote.ashx?t=VRPX&ty=c&ta=1&p=d
👍️0
StockLogistics StockLogistics 3 years ago
“ Litigation

From time to time the Company is subject to claims by third parties under various legal disputes. The defense of such claims, or any adverse outcome relating to any such claims, could have a material adverse effect on the Company’s liquidity, financial condition and cash flows.

On March 12, 2021, the Company and Mr. Mack (the “Defendants”) were named as defendants in a complaint (the “Complaint”) filed by Sorrento Therapeutics, Inc. (“Sorrento”), and Scilex Pharmaceuticals Inc. (“Scilex” and together with Sorrento, the “Plaintiffs”) in the Court of Chancery of the State of Delaware. In the Complaint, the Plaintiffs alleged (i) Mr. Mack breached a Restrictive Covenants Agreement, dated as of November 8, 2016, between himself and Sorrento (the “Restrictive Covenants Agreement”), (ii) the Company tortiously interfered with the Restrictive Covenants Agreement, and (iii) the Company tortiously interfered with Scilex’s relationship with Mr. Mack. On May 7, 2021 Plaintiffs filed an Amended Complaint (the “First Amended Complaint”) asserting the same three causes of action. Simultaneously with filing the original Complaint, Plaintiffs filed a motion to expedite, seeking a hearing on their prospective motion for a preliminary injunction, prohibiting Mr. Mack’s alleged violations of the Restrictive Covenants Agreement and prohibiting the alleged tortious interference. On March 22, 2021, Vice Chancellor Paul A. Fioravanti Jr. issued a scheduling order, setting forth terms which had been agreed to by the parties, under which oral argument on Plaintiffs’ proposed motion for preliminary injunction was scheduled for July 15, 2021. On May 18, 2021, the Vice Chancellor issued a revised scheduling order, also setting forth terms which had been agreed to by the parties, under which Plaintiffs agreed not to move for a preliminary injunction and a trial in the action was set for February 9-11, 2022. On September 28, 2021, Plaintiffs filed a Second Amended Verified Complaint asserting the same three causes of action as the prior complaints, as well as additional claims in which Plaintiffs allege (i) Mr. Mack breached an Employment, Proprietary Information and Inventions Agreement, dated as of October 25, 2016, between himself and Sorrento (the “Employment Agreement”), (ii) the Company tortiously interfered with the Employment Agreement, (iii) Mr. Mack breached his fiduciary duties to Scilex, and (iv) the Company aided and abetted Mr. Mack’s alleged breach of fiduciary duties to Scilex. On October 18, 2021, Defendants filed an Answer to the Second Amended Complaint, and subsequently withdrew a previously filed motion to dismiss the first Amended Complaint. We intend to vigorously defend the action. However, we are unable to predict the ultimate outcome of the lawsuit at this time.


- From the quarterly filing
👍️0
Awl416 Awl416 3 years ago
News
👍️0
JMoneyHoops JMoneyHoops 3 years ago
Adding here
👍️0
ok2buy ok2buy 3 years ago
Company just screwed existing share holders with a $6.00 placement. Shame on you./ok2
👍️0
ok2buy ok2buy 3 years ago
Halted this morning pending news. On my watchlist./ok2
👍️0
ok2buy ok2buy 3 years ago
Back in on the buy, thanks to the seller./ok2
👍️0
ok2buy ok2buy 3 years ago
Also extremely low float on this one. Big money looking to steal your shares today if you let them./ok2
👍️0
ok2buy ok2buy 3 years ago
I see the games are afoot here. Large asks coming into the block, looking to scare retailers holding the stock into selling lower. Don't be intimidated by institutions into selling your shares because they are buying them./ok2
👍️0
ok2buy ok2buy 3 years ago
Oversold on a Friday. Bought and will hold into next week. Good luck to all./ok2buy
👍️0
Jake L Jake L 3 years ago
VRPX - MIDDAY REPORT

👍️0
SurgeGuy2.0 SurgeGuy2.0 3 years ago
Another SCAM play? lolzzzzzz
👍️0
SurgeGuy2.0 SurgeGuy2.0 3 years ago
Ouch! CRASH AND BURN!!!!!! lolzzzzzzzzzzz No COXY ROXY here! lolzzzzz
👍️0
bcapps66 bcapps66 3 years ago
It happens....I was up going into the late afternoon so I went to the beach for an hour just to come back to a disaster haha.
👍️0
thepat45 thepat45 3 years ago
Yeah, not my finest moment for sure.
👍️0
dinogreeves dinogreeves 3 years ago
CHRS is the next big runner, has 50 dollars writen all over it by Monday next week.
👍️0
bcapps66 bcapps66 3 years ago
That didn't work out well....
👍️0
fitzwell11 fitzwell11 3 years ago
Everyone look at NURO on its run. Same pattern. Exploded to $40 they faded it all the way back to $21 then it gapped to
$40 next morning. I don’t think shorts are off the hook here yet. Just my .02
👍️0
thepat45 thepat45 3 years ago
After hours should be interesting then.. Looking for a large spike after close today.
👍️0
Pedro2004 Pedro2004 3 years ago
They're shorting, covering, shorting again, and covering again -- to shake this down.
👍️0
thepat45 thepat45 3 years ago
Can only short but so much... Float is around 2 million shares...
👍️0
Pedro2004 Pedro2004 3 years ago
Damn. They're shorting the hell out of this to keep it down.
👍️0
thepat45 thepat45 3 years ago
Sure, I'll go for a ride...
👍️0
budgetthis budgetthis 3 years ago
Turning over in the $20 + range nicely……..

Elevator going up ?

All Aboard ?

$$ VRPX $$
👍️0
SurgeGuy2.0 SurgeGuy2.0 3 years ago
100% complete BS!!!!! Sorry! lolzzzzzzzz
👍️0
makinezmoney makinezmoney 3 years ago
$VRPX: Get a good broker


Who's your broker ?


THey probably suck



GO $VRPX
👍️0
BUFCARP BUFCARP 3 years ago
They stopped it with the bs halt to save shorts..
👍️0
dinogreeves dinogreeves 3 years ago
I know of one reality, once I get out, I never get back in. Good luck though.
👍️0
Major_Bankz Major_Bankz 3 years ago
Reality here = only 2M Float, with this volume its going much higher.
👍️0
Major_Bankz Major_Bankz 3 years ago
2M Float should be locked by now, this runs to $50+
👍️0
eur06 eur06 3 years ago
True
👍️0
Major_Bankz Major_Bankz 3 years ago
maybe higher, 2M Float is just crazy low.
👍️0
makinezmoney makinezmoney 3 years ago
$VRPX: Catch the next VRPX at $PMCB right now


NO SHARES TO SHORT !!!!!!!



And HALTED right now.


You know how this works :)



GO $VRPX & $PMCB
👍️0
MonstaGains MonstaGains 3 years ago
Weeeeeeeeeee hahaha
👍️0
Major_Bankz Major_Bankz 3 years ago
Volatility halt, should open around $35+
👍️0
Major_Bankz Major_Bankz 3 years ago
looks like its holding strong, with 2M Float this runs to $50+ today
👍️0
cityimport cityimport 3 years ago
Thank you Dino!
congratulation to you too.

Let's get to the next BIG one ;)
👍️0

Your Recent History

Delayed Upgrade Clock